Canaccord Genuity Maintains Buy on Helus Pharma, Raises Price Target to $58
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $42 to $58.
Last updated: 2026-11-19 08:13:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Helus Pharma Inc. (HELP) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $6.88, with a market capitalization of $574.68M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.76 to $15.15. This page covers its latest market performance, valuation, price trends and company information.
$574.68M | |
$7.16 | |
$7.40 | |
$6.70 | |
$7.20 | |
3.09M | |
1.82M | |
-- | |
$15.15 | |
$3.76 | |
-- | |
2026-06-30 |
Helus Pharma Inc. (HELP) last closed at $6.88 as of 2026-11-19 01:00:00, down 4.38% ($0.32) from the previous close of $7.20.
During the latest regular trading session, HELP traded between $6.70 and $7.40, with a volume of 3.09M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Helus Pharma Inc. (HELP) moved from $9.07 to $6.88, representing a decline of 24.17% ($2.19).
The stock traded between $6.70 and $9.83 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 3.39 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 27.4%
HELP is currently trading at $6.88, placing it 27.4% of the way from its 52-week low of $3.76 to its 52-week high of $15.15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
| Employees | 50 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Helus Pharma Inc. and HELP stock.
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $42 to $58.
Helus Pharma reports positive Phase 3 data as adjunctive depression drug HLP003 rapidly reduces symptoms through 12 weeks in adult patients.
U.S. stock futures fell as Aclaris plunged 21% after its dermatitis trial failed; Summit and other stocks also dropped in premarket trading.
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(0.64) by 120.31 percent. This is a 1.44 percent decrease over losses of $(1.39) per share from
Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS) stock rose
Eligible investors can buy real shares of Helus Pharma Inc. (HELP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to HELP, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between HELP shares and USD.
HELP Shares to USD
1.00 HELP shares = 6.878 USD
Calculations are estimates based on the latest available price and are for reference only.